Selected Grants
TBCRC45: AVIATOR: A Phase II Study Of Trastuzumab, Vinorelbine, and Avelumab ± PF-05082566 (4-1BB/CD137 Agonist) in HER2+ MBC
Clinical TrialPrincipal Investigator · Awarded by Johns Hopkins University · 2019 - 2028AFT-05/PALLAS
Clinical TrialPrincipal Investigator · Awarded by Alliance Foundation Trials, LLC · 2016 - 2028A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive
Clinical TrialPrincipal Investigator · Awarded by Alliance Foundation Trials, LLC · 2017 - 2028Randomized, double-blind, phase 3 study of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally-advanced or metastatic HER2+ breast cancer
Clinical TrialPrincipal Investigator · Awarded by Seattle Genetics, Inc · 2019 - 2024Addressing Sexual Concerns in Breast Cancer Survivors: RCT of a Novel Couple-Based Intervention
ResearchCo Investigator · Awarded by Fox Chase Cancer Center · 2018 - 2024Oncothyreon ONT 380-206
ResearchPrincipal Investigator · Awarded by Cascadian Therapeutics Inc. · 2016 - 2023A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor
ResearchPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2015 - 2023Optimizing Delivery of a Behavioral Cancer Pain Intervention Using a SMART
ResearchClinical Associate · Awarded by National Institutes of Health · 2016 - 2022Reimagine End of Life: An Online, Personalized Coping and Decision Aid for Metastatic Breast Cancer Patients and Providers
ResearchCo Investigator · Awarded by Pfizer, Inc. · 2016 - 2018A randomized doubleblind, placebo controlled study of ribociclib in combination w/fulvestrant for the treatment of postmenopausal women w/hormone receptor positive, HER2-, advanced breast cancer who have received no or only 1line of prior endo treatm
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2015 - 2017External Relationships
- Novartis pharmaceuticals
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.